Answers are grounded in this paper and cite their sources.
Linked study demonstrates the impact of GLP-1 receptor agonists on cardiovascular outcomes in type 2 diabetes, suggesting treatment continuity is crucial for benefits.
Use of GLP-1 receptor agonists reduces the risk of cardiovascular events in people with type 2 diabetes, but these benefits may be reduced if treatment is interrupted; a linked study highlights the importance of target trial emulation in evaluating long term treatment strategies and informing future clinical and policy decisions, write Batty and colleaguesGlucagon-like peptide 1 receptor agonists (GLP-1RAs) improve glycaemic control,1 promote weight loss,2 delay progression of kidney disease,3 and reduce major adverse cardiovascular events (including myocardial infarction and stroke)4–6 in people with type 2 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Batty et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: